v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2025
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

​

​

​

​

​

​

​

​

​

​

Year ended December 31, 

​

  ​ ​ ​

2025

  ​ ​ ​

2024

External clinical development expenses

​

$

7,396,788

​

$

2,083,119

Personnel related and stock-based compensation

​

 

1,532,280

​

 

1,073,564

Other research and development expenses

​

 

873,739

​

 

445,949

Total research and development expenses

​

$

9,802,807

​

$

3,602,632